Lupin Q1 Results Review - Sharp Uptick In Revenue, Margins: Systematix

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Systematix Research Report.Lupin Ltd.'s revenue (Rs 55,143 million) and net earnings (Rs 8,013 million) were significantly higher than expectations - 7.2% and 42 % higher respectively. India formulation and North America were the key growth drivers. India growth was 17.5% YoY and was led by a lumpy opportunity (institutional supplies) and hence the growth in subsequent quarters should taper off. North America grew 7% QoQ versus our expectations of low single digit growth. Higher than expected contribution from new launches (Mirabegron, gOracea and gProlensa) helped the outperformance in North America. Going forward in subsequent quarters, we expect North America revenue run rate to inch up from current levels led by new launches. Gross margins were higher 51 basis points QoQ potentially led by the new limited competition launches. Ebitda margins came in stronger led by a improvement in gross margins and lower research and development spend (6.2% of sales). The company expects to sustain gross margins at current levels. Erosion in gSuprep sales offset some of the gains from new launches. Based on our revised forecasts we expect Lupin to deliver revenue /Ebitda / profit after tax compound annual growth rate of 9.8% / 16.9% / 29.3% respectively over FY24-FY26E. While we raise our EPS forecasts for Lupin, we reduce our target PE multiple to 20 times to arrive at a target price of Rs 1,397 and maintain our rating as Sell. .Click on the attachment to read the full report:.Lupin Shares At Eight Year High After Q1 Profit Nearly Doubles, Beats Estimates .DISCLAIMERThis report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Lupin Q1 Results Review - Sharp Uptick In Revenue, Margins: Systematix

Going forward in subsequent quarters, the brokerage expects the company's North America revenue run rate to inch up from current levels led by new launches.

NDTV Profit

NDTV Profit

Follow Us

DOWNLOAD THE APP

Lupin Q1 Results Review - Sharp Uptick In Revenue, Margins: Systematix

Going forward in subsequent quarters, the brokerage expects the company's North America revenue run rate to inch up from current levels led by new launches.

Choose a plan

Follow Us

DOWNLOAD THE APP